Cancer Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers, and Other Cancer Biomarkers), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, and Other Cancers), by End User (Hospitals, Academ

Cancer Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers, and Other Cancer Biomarkers), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, and Other Cancers), by End User (Hospitals, Academic and Cancer Research Institutes, Ambulatory Surgical Centers, and Cancer Diagnostic Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Cancer biomarkers offers great opportunity in improving management of cancer patients by enhancing the efficiency of detection and efficacy of the treatment. Biomarkers of cancer includes various biochemical components such as proteins, sugars, lipids, nucleic acids, small metabolites, cytogenetic and cytokinetic parameters, and whole tumor cells, which are found in body fluid. Molecular alterations used for cancer diagnosis involves application of DNA, RNA, microRNAs, and proteins.

Biomarker testing is a way to look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer. Each person’s cancer has a unique pattern of biomarkers. Some biomarkers affect how certain cancer treatments work. Biomarker testing may help the doctor choose a cancer treatment for you. Biomarker testing for cancer treatment may also be called: tumor testing, tumor genetic testing, genomic testing or genomic profiling, molecular testing or molecular profiling, somatic testing, and tumor subtyping. Biomarker testing is different from genetic testing that is used to find out if someone has inherited mutations that make them more likely to get cancer. Inherited mutations are those you are born with. They are passed on to an individual by parents.

Market Dynamics

Increasing research and development activities in the field of cancer biomarker to develop and identify potential cancer biomarkers for early diagnosis of cancer, is expected to drive growth of the global cancer biomarkers market, in the near future. For instance, in March 2018, a team of researchers from University of Massachusetts and Clarkson University discovered various protein such as human chorionic gonadotropin (hCG), lipoproteins, α1-chymotrypsin and α1-antitrypsin from breast milk, which can act as a potential cancer biomarker in detection of breast cancer.

Key features of the study:

• This report provides an in-depth analysis of the global cancer biomarkers market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cancer biomarkers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include bioMérieux, Inc., INOVIQ, Bio-Rad Laboratories, Inc., Abbott, Becton, Dickinson and Company, Merck KgaA, QIAGEN, Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., and Siemens Healthcare Private Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cancer biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biomarkers market

Detailed Segmentation:

• Global Cancer Biomarkers Market, By Biomarker Type:
• Protein Biomarkers
• Genetic Biomarkers
• Other Cancer Biomarkers
• Global Cancer Biomarkers Market, By Cancer Type:
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Kidney Cancer
• Liver Cancer
• Other Cancers
• Global Cancer Biomarkers Market, By End User:
• Hospitals
• Academic and Cancer Research Institutes
• Ambulatory Surgical Centers
• Cancer Diagnostic Laboratories
• Global Cancer Biomarkers Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• bioMérieux, Inc.
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• INOVIQ
• Bio-Rad Laboratories, Inc.
• Abbott
• Becton, Dickinson and Company
• Merck KGaA
• QIAGEN
• Thermo Fisher Scientific Inc.
• CENTOGENE N.V.
• PerkinElmer Inc.
• Siemens Healthcare Private Limited

“*” marked represents similar segmentation in other categories in the respective section.